Skip to content
2000
image of Immunoglobulin Therapy in Patients with Painful Small Fiber Neuropathy: A Systematic Review

Abstract

Introduction

Small fiber neuropathy (SFN) affects pain and autonomic function, and there is increasing evidence that immune pathways are linked to its pathology. Intravenous immunoglobulin (IVIG) has been proposed as a treatment option for patients with painful SFN but has yielded mixed results. This review evaluates the effectiveness of IVIGs in the treatment of painful SFN.

Methods

According to PRISMA guidelines, a thorough literature search was conducted using five major electronic databases (PubMed, Google Scholar, Scopus, EMBASE, and Web of Science) up to August 17, 2023. Data extraction was performed independently by two reviewers, and quality assessments were performed using Joanna Briggs Institute tools. The PRISMA guidelines ensured the transparency of the review.

Results

This systematic review included seven studies to evaluate the effectiveness of IVIG for the treatment of SFN. The review included 458 patients from various studies conducted between 2005 and 2023, covering various neuropathy subtypes such as idiopathic SFN, sarcoidosis-associated SFN, . Both double-blind RCTs reported no significant differences between IVIG and placebo in neuropathy severity or pain reduction. Retrospective cohort studies varied in quality and produced mixed results. Of note, some studies showed significant pain reduction with IVIG, while others did not. The effectiveness of IVIG on neuropathy severity and intraepidermal nerve fiber density was similarly variable, with some studies reporting efficacy and others indicate no significant changes. Overall, IVIG showed potential benefits, but the results were inconsistent across studies.

Discussion

IVIG shows potential efficacy in select SFN subtypes, particularly autoimmune-associated forms (., TS-HDS/FGFR-3 positive), with some retrospective studies reporting pain and functional improvements. However, two high-quality RCTs found no significant benefit over placebo. Marked heterogeneity in study design, IVIG protocols, diagnostic criteria, and outcome measures limits comparability and generalizability. Adverse events, including infusion reactions were common. These findings highlight IVIG’s possible role in immunologically mediated SFN but underscore the need for standardized protocols, biomarker-based patient selection, and large, well-controlled trials to establish definitive efficacy.

Conclusion

Some evidence suggests the potential benefit of IVIG therapy for certain subgroups of patients with SFN. However, the overall effectiveness is still unclear, and further studies are needed.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crcep/10.2174/0127724328350286250727014322
2025-08-07
2025-09-29

  • From This Site

    /content/journals/crcep/10.2174/0127724328350286250727014322
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Finsterer J. Scorza F.A. Small fiber neuropathy. Acta Neurol. Scand. 2022 145 5 493 503 10.1111/ane.13591 35130356
    [Google Scholar]
  2. Gibbons C.H. Klein C. IVIG and small fiber neuropathy. Neurology 2021 96 20 929 930 10.1212/WNL.0000000000011921 33766998
    [Google Scholar]
  3. Teunissen L.L. Eurelings M. Notermans N.C. Hop J.W. van Gijn J. Quality of life in patients with axonal polyneuropathy. J. Neurol. 2000 247 3 195 199 10.1007/s004150050562 10787114
    [Google Scholar]
  4. Devigili G. Cazzato D. Lauria G. Clinical diagnosis and management of small fiber neuropathy: An update on best practice. Expert Rev. Neurother. 2020 20 9 967 980 10.1080/14737175.2020.1794825 32654574
    [Google Scholar]
  5. Terkelsen A.J. Karlsson P. Lauria G. Freeman R. Finnerup N.B. Jensen T.S. The diagnostic challenge of small fibre neuropathy: Clinical presentations, evaluations, and causes. Lancet Neurol. 2017 16 11 934 944 10.1016/S1474‑4422(17)30329‑0 29029847
    [Google Scholar]
  6. Liu X. Treister R. Lang M. Oaklander A.L. IVIg for apparently autoimmune small-fiber polyneuropathy: First analysis of efficacy and safety. Ther. Adv. Neurol. Disord. 2018 11 1756285617744484 10.1177/1756285617744484 29403541
    [Google Scholar]
  7. Schofield J.R. Chemali K.R. How we treat autoimmune small fiber polyneuropathy with immunoglobulin therapy. Eur. Neurol. 2018 80 5-6 304 310 10.1159/000498858 30889595
    [Google Scholar]
  8. Parambil J.G. Tavee J.O. Zhou L. Pearson K.S. Culver D.A. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir. Med. 2011 105 1 101 105 10.1016/j.rmed.2010.09.015 20926271
    [Google Scholar]
  9. Wakasugi D. Kato T. Gono T. Ito E. Nodera H. Kawaguchi Y. Yamanaka H. Hara M. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren’s syndrome. Mod. Rheumatol. 2009 19 4 437 440 10.3109/s10165‑009‑0180‑2 19458906
    [Google Scholar]
  10. Souayah N. Chin R.L. Brannagan T.H. Latov N. Green P.H.R. Kokoszka A. Sander H.W. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur. J. Neurol. 2008 15 12 1300 1303 10.1111/j.1468‑1331.2008.02305.x 19049545
    [Google Scholar]
  11. Geerts M. de Greef B.T.A. Sopacua M. van Kuijk S.M.J. Hoeijmakers J.G.J. Faber C.G. Merkies I.S.J. Intravenous immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy. Neurology 2021 96 20 e2534 e2545 10.1212/WNL.0000000000011919 33766992
    [Google Scholar]
  12. Elmagarmid AK, Fedorowicz Z, Hammady H, Ilyas IF, Khabsa M, Ouzzani M. Rayyan: A systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews 2016 210
    [Google Scholar]
  13. Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. Shamseer L. Tetzlaff J.M. Akl E.A. Brennan S.E. Chou R. Glanville J. Grimshaw J.M. Hróbjartsson A. Lalu M.M. Li T. Loder E.W. Mayo-Wilson E. McDonald S. McGuinness L.A. Stewart L.A. Thomas J. Tricco A.C. Welch V.A. Whiting P. Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021 372 71 n71 10.1136/bmj.n71 33782057
    [Google Scholar]
  14. Moola S. Munn Z. Sears K. Sfetcu R. Currie M. Lisy K. Tufanaru C. Qureshi R. Mattis P. Mu P. Conducting systematic reviews of association (etiology). Int. J. Evid.-Based Healthc. 2015 13 3 163 169 10.1097/XEB.0000000000000064 26262566
    [Google Scholar]
  15. Barker TH Stone JC Sears K Klugar M Leonardi-Bee J Tufanaru C Revising the JBI quantitative critical appraisal tools to improve their applicability: An overview of methods and the development process. JBI Evid Synth 2023 21 3 10.11124/JBIES‑22‑00125
    [Google Scholar]
  16. Tij Benno Thole MS JBI critical appraisal checklist for cohort studies. 2020 Available from: https://jbi.global/sites/default/files/2020-08/Checklist_for_Cohort_Studies.pdf
  17. Higgins J.P.T. Altman D.G. Gøtzsche P.C. Jüni P. Moher D. Oxman A.D. Savovic J. Schulz K.F. Weeks L. Sterne J.A.C. Cochrane Bias Methods Group Cochrane Statistical Methods Group The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011 343 oct18 2 d5928 10.1136/bmj.d5928 22008217
    [Google Scholar]
  18. Zeng X. Zhang Y. Kwong J.S.W. Zhang C. Li S. Sun F. Niu Y. Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta‐analysis, and clinical practice guideline: A systematic review. J. Evid. Based Med. 2015 8 1 2 10 10.1111/jebm.12141 25594108
    [Google Scholar]
  19. Melo G. Dutra K.L. Rodrigues Filho R. Ortega A.O.L. Porporatti A.L. Dick B. Flores-Mir C. De Luca Canto G. Association between psychotropic medications and presence of sleep bruxism: A systematic review. J. Oral Rehabil. 2018 45 7 545 554 10.1111/joor.12633 29663484
    [Google Scholar]
  20. Chompoopong P. Rezk M. Mirman I. Berini S.E. Dyck P.J.B. Mauermann M. Shouman K. Klein C. Mills J.R. Dubey D. TS-HDS autoantibody: Clinical characterization and utility from real-world tertiary care center experience. J. Neurol. 2023 270 9 4523 4528 10.1007/s00415‑023‑11798‑9 37294321
    [Google Scholar]
  21. Gibbons C.H. Rajan S. Senechal K. Hendry E. McCallister B. Levine T.D. A double‐blind placebo‐controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS‐HDS and FGFR ‐3 autoantibodies. Muscle Nerve 2023 67 5 363 370 10.1002/mus.27745 36367813
    [Google Scholar]
  22. Zeidman L.A. Saini P. Mai P. Immune-mediated small fiber neuropathy with trisulfated heparin disaccharide, fibroblast growth factor receptor 3, or Plexin D1 antibodies: Presentation and treatment with intravenous immunoglobulin. J. Clin. Neuromuscul. Dis. 2022 24 1 26 37 10.1097/CND.0000000000000423 36005471
    [Google Scholar]
  23. Mori K. Iijima M. Koike H. Hattori N. Tanaka F. Watanabe H. Katsuno M. Fujita A. Aiba I. Ogata A. Saito T. Asakura K. Yoshida M. Hirayama M. Sobue G. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain 2005 128 11 2518 2534 10.1093/brain/awh605 16049042
    [Google Scholar]
  24. Tavee J.O. Karwa K. Ahmed Z. Thompson N. Parambil J. Culver D.A. Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir. Med. 2017 126 135 138 10.1016/j.rmed.2017.03.011 28318820
    [Google Scholar]
  25. Zeidman L.A. Kubicki K. Clinical features and treatment response in immune-mediated small fiber neuropathy with trisulfated heparin disaccharide or fibroblast growth factor receptor 3 antibodies. J. Clin. Neuromuscul. Dis. 2021 22 4 192 199 10.1097/CND.0000000000000355 34019003
    [Google Scholar]
  26. Guilpain P. Kaveri S.V. Mouthon L.U.C. Autoantibodies in therapeutic preparations of human intravenous Immunoglobulin (IVIG). Autoantibodies. 2nd ed Burlington Elsevier 2007 293 298 10.1016/B978‑044452763‑9/50043‑3
    [Google Scholar]
  27. Oaklander A.L. Dalakas M.C. Reader response: Intravenous immunoglobulin therapy in patients with painful idiopathic small-fiber neuropathy. Neurology 2022 99 15 675 676 10.1212/WNL.0000000000201313 36216520
    [Google Scholar]
  28. Nobile-Orazio E. Terenghi F. IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. J. Neurol. 2005 252 S1 i7 i13 Suppl. 1 10.1007/s00415‑005‑1103‑6 15959669
    [Google Scholar]
  29. Bakkers M. Merkies I.S.J. Lauria G. Devigili G. Penza P. Lombardi R. Hermans M.C.E. van Nes S.I. De Baets M. Faber C.G. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009 73 14 1142 1148 10.1212/WNL.0b013e3181bacf05 19805731
    [Google Scholar]
  30. Keddie S. Eftimov F. van den Berg L.H. Brassington R. de Haan R.J. van Schaik I.N. Immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst. Rev. 2022 1 1 CD004429 35015296
    [Google Scholar]
  31. Sommer C. Geber C. Young P. Forst R. Birklein F. Schoser B. Polyneuropathies. Dtsch. Arztebl. Int. 2018 115 6 83 90 29478436
    [Google Scholar]
  32. Rist S. Sellam J. Hachulla E. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: A national multicentric retrospective study. Arthritis Care Res. 2011 63 9 1339 10.1002/acr.20495
    [Google Scholar]
  33. Vermeulen M. van Doorn P.A. Brand A. Strengers P.F. Jennekens F.G. Busch H.F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol., Neurosurg. Psychiatr. 1993 56 1 36 39 8488211
    [Google Scholar]
  34. Khoo A. Frasca J. Schultz D. Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Biomark. Res. 2019 7 1 3 10.1186/s40364‑019‑0154‑2 30805188
    [Google Scholar]
  35. Lazarus A.H. Mechanisms of action and immunomodulation by IVIg. Antibody therapy: Substitution – immunomodulation – monoclonal Immunotherapy. Cham Springer International Publishing 2018 73 83 10.1007/978‑3‑319‑68038‑5_6
    [Google Scholar]
  36. Samuelsson A. Towers T.L. Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 291 5503 484 486 10.1126/science.291.5503.484 11161202
    [Google Scholar]
  37. Segú-Vergés C. Caño S. Calderón-Gómez E. Bartra H. Sardon T. Kaveri S. Terencio J. Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system. Front. Immunol. 2022 13 901872 10.3389/fimmu.2022.901872 36248801
    [Google Scholar]
  38. Falco P. Galosi E. Di Stefano G. Leone C. Di Pietro G. Tramontana L. De Stefano G. Litewczuk D. Esposito N. Truini A. Autonomic small-fiber pathology in patients with fibromyalgia. J. Pain 2024 25 1 64 72 10.1016/j.jpain.2023.07.020 37524221
    [Google Scholar]
  39. Katz U. Achiron A. Sherer Y. Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun. Rev. 2007 6 4 257 259 10.1016/j.autrev.2006.08.011 17317619
    [Google Scholar]
  40. Hoffmann J.H.O. Enk A.H. High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease. Front. Immunol. 2019 10 1090 10.3389/fimmu.2019.01090 31244821
    [Google Scholar]
  41. Misbah S.A. Chapel H.M. Adverse effects of intravenous immunoglobulin. Drug Saf. 1993 9 4 254 262 10.2165/00002018‑199309040‑00003 8260119
    [Google Scholar]
  42. Berger M. McCallus D.E. Lin C.S.Y. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J. Peripher. Nerv. Syst. 2013 18 4 275 296 10.1111/jns5.12048 24200120
    [Google Scholar]
  43. Hughes RAC Mehndiratta MM Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2015 1 10.1002/14651858.CD002062.pub3
    [Google Scholar]
  44. Oaklander AL Lunn MPT Hughes RAC van Schaik IN Frost C Chalk CH Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): An overview of systematic reviews. Cochrane Database Syst Rev 2017 1 10.1002/14651858.CD010369.pub2
    [Google Scholar]
  45. Wilson J.C. Sarsour K. Collinson N. Tuckwell K. Musselman D. Klearman M. Napalkov P. Jick S.S. Stone J.H. Meier C.R. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case–control analysis. Semin. Arthritis Rheum. 2017 46 6 819 827 10.1016/j.semarthrit.2016.11.006 28040244
    [Google Scholar]
  46. Rice J.B. White A.G. Scarpati L.M. Wan G. Nelson W.W. Long-term systemic corticosteroid exposure: A systematic literature review. Clin. Ther. 2017 39 11 2216 2229 10.1016/j.clinthera.2017.09.011 29055500
    [Google Scholar]
  47. Kleyman I. Brannagan T.H. III Treatment of chronic inflammatory demyelinating polyneuropathy. Curr. Neurol. Neurosci. Rep. 2015 15 7 47 10.1007/s11910‑015‑0563‑z 26008811
    [Google Scholar]
  48. Li P. Zheng Y. Chen X. Drugs for autoimmune inflammatory diseases: From small molecule compounds to Anti-TNF biologics. Front. Pharmacol. 2017 8 460 10.3389/fphar.2017.00460 28785220
    [Google Scholar]
  49. Humphry N. The efficacy of Anti-TNFs in immune-mediated disease. EMJ. Gastroenterol. 2022 115 2 9 10.33590/emjgastroenterol/10102824
    [Google Scholar]
  50. Schmidt E. Hunzelmann N. Zillikens D. Bröcker E.B. Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin. Exp. Dermatol. 2006 31 4 503 508 10.1111/j.1365‑2230.2006.02151.x 16716150
    [Google Scholar]
  51. von Borstel A. Abdulahad W.H. Dekkema G. Rutgers A. Stegeman C.A. Veldman J. Heeringa P. Sanders J.S. Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production. PLoS One 2020 15 7 e0235743 10.1371/journal.pone.0235743 32645052
    [Google Scholar]
  52. Kridin K. Mruwat N. Amber K.T. Ludwig R.J. Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br. J. Dermatol. 2023 188 4 499 505 10.1093/bjd/ljac118 36763798
    [Google Scholar]
  53. Espiritu A.I. Pasco P.M.D. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult. Scler. Relat. Disord. 2019 33 22 32 10.1016/j.msard.2019.05.011 31136907
    [Google Scholar]
  54. Conrad C. Di Domizio J. Mylonas A. Belkhodja C. Demaria O. Navarini A.A. Lapointe A.K. French L.E. Vernez M. Gilliet M. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat. Commun. 2018 9 1 25 10.1038/s41467‑017‑02466‑4 29295985
    [Google Scholar]
  55. Norris P.A.A. Kaur G. Lazarus A.H. New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases. Curr. Opin. Hematol. 2020 27 6 392 398 10.1097/MOH.0000000000000609 32868670
    [Google Scholar]
  56. Molenaar D.S. de Haan R. Vermeulen M. Impairment, disability, or handicap in peripheral neuropathy: Analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies. J. Neurol. Neurosurg. Psychiatry 1995 59 2 165 169 10.1136/jnnp.59.2.165 7629531
    [Google Scholar]
  57. Themistocleous A.C. Crombez G. Baskozos G. Bennett D.L. Using stratified medicine to understand, diagnose, and treat neuropathic pain. Pain 2018 159 1 S31 S42 Suppl. 1 10.1097/j.pain.0000000000001301 30113945
    [Google Scholar]
  58. Levine T.D. Kafaie J. Zeidman L.A. Saperstein D.S. Massaquoi R. Bland R.J. Pestronk A. Cryptogenic small‐fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptor‐3. Muscle Nerve 2020 61 4 512 515 10.1002/mus.26748 31650561
    [Google Scholar]
/content/journals/crcep/10.2174/0127724328350286250727014322
Loading
Immunoglobulin Therapy in Patients with Painful Small Fiber Neuropathy: A Systematic Review
Bentham Science Publishers ; https://doi.org/10.2174/0127724328350286250727014322
/content/journals/crcep/10.2174/0127724328350286250727014322
/content/journals/crcep/10.2174/0127724328350286250727014322
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article. Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: immunoglobulins ; small nerve fiber neuropathy ; pain management ; infusion reactions ; Neuropathy ; IVIG

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test